

Seoul International Digestive Disease Symposium 2025

In Conjunction with the Annual Meeting of the Korean Society of Gastroenterology

April 19-20, 2025 | Swiss Grand Hotel Seoul, Korea



SIDDS 2025

Frontiers in Digestive Research and Practice

Name	Tomomi Kogiso
Affiliation	Tokyo Women's Medical University (TWMU), Institute of Gastroenterology, Department of Internal Medicine.
Country	Japan
Major Field	Steatohepatitis, Liver failure, Fontan associated liver disease

Educational Background

1991-1997; Tokyo Women's Medical College, Tokyo, Japan

Professional Experience

1997- 1999	TWMU (resident)
1999- 2001	Work at the affiliated hospitals
2001- 2003	TWMU (assistant)
2003- 2006	International Medical center of Japan
2006- 2009	Dept. of Cellular & Molecular Medicine in University of California, San Diego, Howard Hughes Medical Institute (HHMI)
2009-2015	TWMU (assistant)
2015-2019	TWMU (associate lecturer)
2019-present	TWMU (lecturer)

Main Scientific Publications

1. Kogiso T, Ogasawara Y, Taniai M, Shimada E, Inai K, Tokushige K, Nakai Y. Impact of ursodeoxycholic acid treatment on Fontan-associated liver disease. *J Gastroenterol*. 2024. In press.
2. Kogiso T, Tokuhara D, Ohfuji S, Tanaka A, Kanto T. Evaluation of diagnostic criteria for mild-to-advanced stages of Fontan-associated liver disease: A nationwide epidemiological survey in Japan. *Hepatol Res*. 2024. In press.
3. Yamamoto A, Nagao M, Inoue A, Nakao R, Sakai R, Nishina Y, Morita S, Sakai A, Kogiso T, Kaneko K, Tokushige K, Inai K, Sakai S, Yamaguchi J. Prediction of hepatocellular carcinoma in patients with Fontan-associated liver disease using gadolinium ethoxybenzyl diethylenetriamine pentaacetic acid magnetic resonance imaging. *Hepatol Res*. 2024. In press.
4. Kogiso T, Ogasawara Y, Taniai M, Shimada E, Inai K, Tokushige K, Nakai Y. Importance of gamma-glutamyl transferase elevation in patients with Fontan-associated liver disease. *Hepatol Res*. 2024;54:1205-1214.
5. Ohfuji S, Tanaka A, Kogiso T, Kanto T. Epidemiology of Fontan-associated liver disease in Japan: Results from a nationwide survey in 2021. *Hepatol Res*. 2024;54:931-941.



Main Scientific Publications

6. Kogiso T, Takayanagi K, Ishizuka T, Otsuka M, Inai K, Ogasawara Y, Horiuchi K, Taniai M, Tokushige K. Serum level of full-length connective tissue growth factor reflects liver fibrosis stage in patients with Fontan-associated liver disease. *PLoS One*. 2024;19:e0296375.
7. Kogiso T, Ogasawara Y, Horiuchi K, Taniai M, Tokushige K. Analysis of genetic factors associated with fatty liver disease-related hepatocellular carcinoma. *Cancer Medicine*. 2023;12:17798-17807.
8. Kogiso T. Algorithm of ascites management for liver cirrhosis in the tolvaptan era: Paradigm shift treatment improves the outcomes of cirrhotic patients? *Hepatology Res*. 2023;53:791-793.
9. Ogasawara Y, Kogiso T, Horiuchi K, Taniai M, Tokushige K. Outcomes of fatty liver disease with and without metabolic comorbidities and risk factors for mortality. *JGH Open*. 2023, 7:410-418.
10. Kogiso T, Sagawa T, Taniai M, Shimada E, Inai K, Shinohara T, Tokushige K. Risk factors for Fontan-associated hepatocellular carcinoma. *PLOS One*. 2022, 17:e0270230.
11. Horiuchi K, Kogiso T, Sagawa T, Taniai M, Kotera Y, Egawa H, Tokushige K. Prevalence of fatty liver disease after liver transplantation and risk factors for recipients and donors. *Ann Hepatol*. 2022 ;27:100670.
12. Kogiso T, Ogasawara Y, Sagawa T, Taniai M, Tokushige K. Risk and protective factors of acute kidney injury in decompensated cirrhotic patients with ascites on tolvaptan. *JGH Open*. 2021;5:1298-1305.
13. Kogiso T, Sagawa T, Kodama K, Taniai M, Hashimoto E, Tokushige K. Outcomes of Japanese patients with non-alcoholic fatty liver disease according to genetic background and lifestyle-related diseases. *Ann Hepatol*. 2021:100260.
14. Kogiso T, Tokushige K. The Current View of Nonalcoholic Fatty Liver Disease-Related Hepatocellular Carcinoma. *Cancers (Basel)*. 2021;13:516.
15. Kogiso T, Sagawa T, Kodama K, Taniai M, Hashimoto E, Tokushige K. Development and course of diabetes according to genetic factors and diabetes treatment among patients with nonalcoholic fatty liver disease. *Nutrition*. 2021;83:111080.
16. Kogiso T, Tokushige K. Fontan-associated liver disease and hepatocellular carcinoma in adults. *Sci Rep*. 2020;10:21742.
17. Kogiso T, Hashimoto E. Are low triglyceride levels the cause or an outcome of advanced liver fibrosis in elderly patients with nonalcoholic fatty liver disease? *J Gastroenterol Hepatol*. 2020;35:1459-1460.
18. Sagawa T, Kogiso T, Sugiyama H, Hashimoto E, Yamamoto M, Tokushige K. Characteristics of hepatocellular carcinoma arising from Fontan-associated liver disease. *Hepatology Res*. 2020; 50:853-862.
19. Kogiso T, Sagawa T, Kodama K, Taniai M, Hashimoto E, Tokushige K. Long-term outcomes of non-alcoholic fatty liver disease and the risk factors for mortality and hepatocellular carcinoma in a Japanese population. *J Gastroenterol Hepatol*. 2020;35:1579-1589.